{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T18:23:41Z","timestamp":1790533421412,"version":"4.1.0"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,5,22]],"date-time":"2018-05-22T00:00:00Z","timestamp":1526947200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,5,22]],"date-time":"2018-05-22T00:00:00Z","timestamp":1526947200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>T- and NK-cell lymphomas (TCL) are a heterogenous group of lymphoid malignancies with poor prognosis. In contrast to B-cell and myeloid malignancies, there are few preclinical models of TCLs, which has hampered the development of effective therapeutics. Here we establish and characterize preclinical models of TCL. We identify multiple vulnerabilities that are targetable with currently available agents (e.g., inhibitors of JAK2 or IKZF1) and demonstrate proof-of-principle for biomarker-driven therapies using patient-derived xenografts (PDXs). We show that MDM2 and MDMX are targetable vulnerabilities within <jats:italic>TP53<\/jats:italic>-wild-type TCLs. ALRN-6924, a stapled peptide that blocks interactions between p53 and both MDM2 and MDMX has potent in vitro activity and superior in vivo activity across 8 different PDX models compared to the standard-of-care agent romidepsin. ALRN-6924 induced a complete remission in a patient with <jats:italic>TP53<\/jats:italic>-wild-type angioimmunoblastic T-cell lymphoma, demonstrating the potential for rapid translation of discoveries from subtype-specific preclinical models.<\/jats:p>","DOI":"10.1038\/s41467-018-04356-9","type":"journal-article","created":{"date-parts":[[2018,5,16]],"date-time":"2018-05-16T15:04:42Z","timestamp":1526483082000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":103,"title":["Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical models"],"prefix":"10.1038","volume":"9","author":[{"given":"Samuel Y.","family":"Ng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriaki","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda L.","family":"Christie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1897-2265","authenticated-orcid":false,"given":"Mahmoud","family":"Ghandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5048-067X","authenticated-orcid":false,"given":"Neekesh V.","family":"Dharia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Dempster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kay","family":"Shigemori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara N.","family":"Morrow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandria","family":"Van Scoyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas A.","family":"Cordero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen E.","family":"Stevenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maneka","family":"Puligandla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Haas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Lo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1802-7231","authenticated-orcid":false,"given":"Robin","family":"Meyers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3143-9270","authenticated-orcid":false,"given":"Galen","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0470-0111","authenticated-orcid":false,"given":"Andrew","family":"Cherniack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Abner","family":"Louissaint","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Nardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron R.","family":"Thorner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xintao","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth A.","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Dorfman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danilo","family":"Fiore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan L.","family":"Epstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmet","family":"Dogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven M.","family":"Horwitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric D.","family":"Jacobsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solimar","family":"Santiago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Guo","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Guerlavais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. Allen","family":"Annis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Aivado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mansoor N.","family":"Saleh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amitkumar","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3797-1877","authenticated-orcid":false,"given":"Aviad","family":"Tsherniak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Root","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisca","family":"Vazquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2840-9791","authenticated-orcid":false,"given":"William C.","family":"Hahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Inghirami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon C.","family":"Aster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8724-3907","authenticated-orcid":false,"given":"David M.","family":"Weinstock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael","family":"Koch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,5,22]]},"reference":[{"key":"4356_CR1","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow, S. H. et al. The2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127, 2375\u20132390 (2016).","journal-title":"Blood"},{"key":"4356_CR2","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1182\/blood-2014-04-573089","volume":"124","author":"F Ellin","year":"2014","unstructured":"Ellin, F., Landstrom, J., Jerkeman, M. & Relander, T. Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry. Blood 124, 1570\u20131577 (2014).","journal-title":"Blood"},{"key":"4356_CR3","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1038\/ng.3967","volume":"49","author":"U Ben-David","year":"2017","unstructured":"Ben-David, U. et al. Patient-derived xenografts undergo mouse-specific tumor evolution. Nat. Genet. 49, 1567\u20131575 (2017).","journal-title":"Nat. Genet."},{"key":"4356_CR4","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.ccell.2016.03.008","volume":"29","author":"EC Townsend","year":"2016","unstructured":"Townsend, E. C. et al. The public repository of xenografts enables discovery and randomized phase II-like trials in mice. Cancer Cell. 29, 574\u2013586 (2016).","journal-title":"Cancer Cell."},{"key":"4356_CR5","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.ccell.2015.03.006","volume":"27","author":"R Crescenzo","year":"2015","unstructured":"Crescenzo, R. et al. Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma. Cancer Cell. 27, 516\u2013532 (2015).","journal-title":"Cancer Cell."},{"key":"4356_CR6","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/ng.2873","volume":"46","author":"T Palomero","year":"2014","unstructured":"Palomero, T. et al. Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas. Nat. Genet. 46, 166\u2013170 (2014).","journal-title":"Nat. Genet."},{"key":"4356_CR7","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1038\/ng.2872","volume":"46","author":"M Sakata-Yanagimoto","year":"2014","unstructured":"Sakata-Yanagimoto, M. et al. Somatic RHOA mutation in angioimmunoblastic T cell lymphoma. Nat. Genet. 46, 171\u2013175 (2014).","journal-title":"Nat. Genet."},{"key":"4356_CR8","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1182\/blood-2017-02-768234","volume":"130","author":"J Park","year":"2017","unstructured":"Park, J. et al. Genomic analysis of 220 CTCLs identifies a novel recurrent gain-of-function alteration in RLTPR (p.Q575E). Blood 130, 1430\u20131440 (2017).","journal-title":"Blood"},{"key":"4356_CR9","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1182\/blood-2014-04-571091","volume":"124","author":"ER Parrilla Castellar","year":"2014","unstructured":"Parrilla Castellar, E. R. et al. ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. Blood 124, 1473\u20131480 (2014).","journal-title":"Blood"},{"key":"4356_CR10","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1182\/blood-2012-03-419937","volume":"120","author":"G Vasmatzis","year":"2012","unstructured":"Vasmatzis, G. et al. Genome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral T-cell lymphomas. Blood 120, 2280\u20132289 (2012).","journal-title":"Blood"},{"key":"4356_CR11","doi-asserted-by":"publisher","first-page":"3768","DOI":"10.1182\/blood-2014-07-588434","volume":"124","author":"T Velusamy","year":"2014","unstructured":"Velusamy, T. et al. A novel recurrent NPM1-TYK2 gene fusion in cutaneous CD30-positive lymphoproliferative disorders. Blood 124, 3768\u20133771 (2014).","journal-title":"Blood"},{"key":"4356_CR12","doi-asserted-by":"crossref","unstructured":"Boddicker, R. L. et al.\u00a0Integrated mate-pair and RNA sequencing identifies novel, targetable gene fusions in peripheral T-cell lymphoma. Blood 128, 1234-1245 (2016).\u00a0","DOI":"10.1182\/blood-2016-03-707141"},{"key":"4356_CR13","doi-asserted-by":"publisher","first-page":"e53767","DOI":"10.1371\/journal.pone.0053767","volume":"8","author":"S Ehrentraut","year":"2013","unstructured":"Ehrentraut, S. et al. t(8;9)(p22; p24)\/PCM1-JAK2 activates SOCS2 and SOCS3 via STAT5. PLoS ONE 8, e53767 (2013).","journal-title":"PLoS ONE"},{"key":"4356_CR14","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.cell.2017.06.010","volume":"170","author":"A Tsherniak","year":"2017","unstructured":"Tsherniak, A. et al. Defining a cancer dependency map. Cell 170, 564\u2013576 e516 (2017).","journal-title":"Cell"},{"key":"4356_CR15","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1182\/blood-2014-08-594507","volume":"125","author":"A Weilemann","year":"2015","unstructured":"Weilemann, A. et al. Essential role of IRF4 and MYC signaling for survival of anaplastic large cell lymphoma. Blood 125, 124\u2013132 (2015).","journal-title":"Blood"},{"key":"4356_CR16","doi-asserted-by":"publisher","first-page":"3118","DOI":"10.1182\/blood-2014-05-578575","volume":"125","author":"RL Boddicker","year":"2015","unstructured":"Boddicker, R. L. et al. The oncogenic transcription factor IRF4 is regulated by a novel CD30\/NF-kappaB positive feedback loop in peripheral T-cell lymphoma. Blood 125, 3118\u20133127 (2015).","journal-title":"Blood"},{"key":"4356_CR17","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3390\/cancers10010021","volume":"10","author":"C Bandini","year":"2018","unstructured":"Bandini, C. et al. IRF4 mediates the oncogenic effects of STAT3 in anaplastic large cell lymphomas. Cancers 10,\u00a021 (2018).","journal-title":"Cancers"},{"key":"4356_CR18","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1126\/science.1244851","volume":"343","author":"J Kronke","year":"2014","unstructured":"Kronke, J. et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science 343, 301\u2013305 (2014).","journal-title":"Science"},{"key":"4356_CR19","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1084\/jem.20161903","volume":"214","author":"F Wiede","year":"2017","unstructured":"Wiede, F. et al. PTPN2 regulates T cell lineage commitment and alphabeta versus gammadelta specification. J. Exp. Med. 214, 2733\u20132758 (2017).","journal-title":"J. Exp. Med."},{"key":"4356_CR20","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/nature23270","volume":"547","author":"RT Manguso","year":"2017","unstructured":"Manguso, R. T. et al. In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target. Nature 547, 413\u2013418 (2017).","journal-title":"Nature"},{"key":"4356_CR21","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1200\/JCO.2017.35.15_suppl.2505","volume":"35","author":"F Meric-Bernstam","year":"2017","unstructured":"Meric-Bernstam, F. al. e. Phase I trial of a novel stapled peptide ALRN-6924 disrupting MDMX- and MDM2-mediated inhibition of WT p53 in patients with solid tumors and lymphomas. J. Clin. Oncol. 35, 2505 (2017).","journal-title":"J. Clin. Oncol."},{"key":"4356_CR22","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s10585-007-9084-8","volume":"24","author":"P Dong","year":"2007","unstructured":"Dong, P. et al. p53 dominant-negative mutant R273H promotes invasion and migration of human endometrial cancer HHUA cells. Clin. Exp. Metastas. 24, 471\u2013483 (2007).","journal-title":"Clin. Exp. Metastas."},{"key":"4356_CR23","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1158\/1078-0432.CCR-14-2249","volume":"21","author":"S Jain","year":"2015","unstructured":"Jain, S. et al. Preclinical pharmacologic evaluation of pralatrexate and romidepsin confirms potent synergy of the combination in a murine model of human T-cell lymphoma. Clin. Cancer Res. 21, 2096\u20132106 (2015).","journal-title":"Clin. Cancer Res."},{"key":"4356_CR24","doi-asserted-by":"publisher","first-page":"2869","DOI":"10.1016\/j.ejca.2013.04.029","volume":"49","author":"F Morschhauser","year":"2013","unstructured":"Morschhauser, F. et al. A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial. Eur. J. Cancer 49, 2869\u20132876 (2013).","journal-title":"Eur. J. Cancer"},{"key":"4356_CR25","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1038\/ng.587","volume":"42","author":"M Kleppe","year":"2010","unstructured":"Kleppe, M. et al. Deletion of the protein tyrosine phosphatase gene PTPN2 in T-cell acute lymphoblastic leukemia. Nat. Genet. 42, 530\u2013535 (2010).","journal-title":"Nat. Genet."},{"key":"4356_CR26","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1038\/ng.3909","volume":"49","author":"Y Liu","year":"2017","unstructured":"Liu, Y. et al. The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia. Nat. Genet. 49, 1211\u20131218 (2017).","journal-title":"Nat. Genet."},{"key":"4356_CR27","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/S0960-9822(02)00697-8","volume":"12","author":"PD Simoncic","year":"2002","unstructured":"Simoncic, P. D., Lee-Loy, A., Barber, D. L., Tremblay, M. L. & McGlade, C. J. The T cell protein tyrosine phosphatase is a negative regulator of janus family kinases 1 and 3. Curr. Biol. 12, 446\u2013453 (2002).","journal-title":"Curr. Biol."},{"key":"4356_CR28","doi-asserted-by":"publisher","first-page":"4758","DOI":"10.1172\/JCI59492","volume":"121","author":"F Wiede","year":"2011","unstructured":"Wiede, F. et al. T cell protein tyrosine phosphatase attenuates T cell signaling to maintain tolerance in mice. J. Clin. Invest. 121, 4758\u20134774 (2011).","journal-title":"J. Clin. Invest."},{"key":"4356_CR29","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.3324\/haematol.2011.041921","volume":"96","author":"M Kleppe","year":"2011","unstructured":"Kleppe, M. et al. Mutation analysis of the tyrosine phosphatase PTPN2 in Hodgkin\u2019s lymphoma and T-cell non-Hodgkin\u2019s lymphoma. Haematologica 96, 1723\u20131727 (2011).","journal-title":"Haematologica"},{"key":"4356_CR30","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/nm.4062","volume":"22","author":"S Shojaee","year":"2016","unstructured":"Shojaee, S. et al. PTEN opposes negative selection and enables oncogenic transformation of pre-B cells. Nat. Med. 22, 379\u2013387 (2016).","journal-title":"Nat. Med."},{"key":"4356_CR31","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/nrc.2017.111","volume":"18","author":"M Muschen","year":"2018","unstructured":"Muschen, M. Autoimmunity checkpoints as therapeutic targets in B cell malignancies. Nat. Rev. Cancer 18, 103\u2013116 (2018).","journal-title":"Nat. Rev. Cancer."},{"key":"4356_CR32","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1182\/blood-2014-03-559542","volume":"124","author":"MJ Kiel","year":"2014","unstructured":"Kiel, M. J. et al. Integrated genomic sequencing reveals mutational landscape of T-cell prolymphocytic leukemia. Blood 124, 1460\u20131472 (2014).","journal-title":"Blood"},{"key":"4356_CR33","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1093\/jnci\/82.6.501","volume":"82","author":"M Beckwith","year":"1990","unstructured":"Beckwith, M., Longo, D. L., O\u2019Connell, C. D., Moratz, C. M. & Urba, W. J. Phorbol ester-induced, cell-cycle-specific, growth inhibition of human B-lymphoma cell lines. J. Natl. Cancer Inst. 82, 501\u2013509 (1990).","journal-title":"J. Natl. Cancer Inst."},{"key":"4356_CR34","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1159\/000150340","volume":"36","author":"M Shimakage","year":"1993","unstructured":"Shimakage, M. et al. A Ki-1-positive cell line expressing Epstein-Barr virus antigens, established from a child with Ki-1-positive lymphoma. Intervirology 36, 215\u2013224 (1993).","journal-title":"Intervirology"},{"key":"4356_CR35","doi-asserted-by":"publisher","first-page":"2312","DOI":"10.1128\/MCB.17.4.2312","volume":"17","author":"D Bischof","year":"1997","unstructured":"Bischof, D., Pulford, K., Mason, D. Y. & Morris, S. W. Role of the nucleophosmin (NPM) portion of the non-Hodgkin\u2019s lymphoma-associated NPM-anaplastic lymphoma kinase fusion protein in oncogenesis. Mol. Cell. Biol. 17, 2312\u20132325 (1997).","journal-title":"Mol. Cell. Biol."},{"key":"4356_CR36","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1002\/1097-0142(197811)42:5<2379::AID-CNCR2820420539>3.0.CO;2-4","volume":"42","author":"AL Epstein","year":"1978","unstructured":"Epstein, A. L. et al. Biology of the human malignant lymphomas. IV. Functional characterization of ten diffuse histiocytic lymphoma cell lines. Cancer 42, 2379\u20132391 (1978).","journal-title":"Cancer"},{"key":"4356_CR37","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1080\/10428190210193","volume":"43","author":"H Merz","year":"2002","unstructured":"Merz, H. et al. Characterization of a novel human anaplastic large cell lymphoma cell line tumorigenic in SCID mice. Leuk. Lymphoma 43, 165\u2013172 (2002).","journal-title":"Leuk. Lymphoma"},{"key":"4356_CR38","doi-asserted-by":"publisher","first-page":"5795","DOI":"10.1182\/blood-2011-12-396150","volume":"119","author":"M Travert","year":"2012","unstructured":"Travert, M. et al. Molecular features of hepatosplenic T-cell lymphoma unravels potential novel therapeutic targets. Blood 119, 5795\u20135806 (2012).","journal-title":"Blood"},{"key":"4356_CR39","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/S0145-2126(02)00023-1","volume":"26","author":"Y Matsuo","year":"2002","unstructured":"Matsuo, Y., Drexler, H. G., Takeuchi, M., Tanaka, M. & Orita, K. Establishment of the T-cell large granular lymphocyte leukemia cell line MOTN-1 carrying natural killer-cell antigens. Leuk. Res. 26, 873\u2013879 (2002).","journal-title":"Leuk. Res."},{"key":"4356_CR40","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1182\/blood.V72.1.234.234","volume":"72","author":"P Fischer","year":"1988","unstructured":"Fischer, P. et al. A Ki-1 (CD30)-positive human cell line (Karpas 299) established from a high-grade non-Hodgkin\u2019s lymphoma, showing a 2;5 translocation and rearrangement of the T-cell receptor beta-chain gene. Blood 72, 234\u2013240 (1988).","journal-title":"Blood"},{"key":"4356_CR41","first-page":"1047","volume":"7","author":"MJ Dyer","year":"1993","unstructured":"Dyer, M. J. et al. A new human T-cell lymphoma cell line (Karpas 384) of the T-cell receptor gamma\/delta lineage with translocation t(7:14) (p13; q11.2). Leukemia 7, 1047\u20131053 (1993).","journal-title":"Leukemia"},{"key":"4356_CR42","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/BF02631086","volume":"28A","author":"K Kaltoft","year":"1992","unstructured":"Kaltoft, K. et al. Establishment of two continuous T-cell strains from a single plaque of a patient with mycosis fungoides. In. Vitr. Cell. Dev. Biol. 28A, 161\u2013167 (1992).","journal-title":"In. Vitr. Cell. Dev. Biol."},{"key":"4356_CR43","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1084\/jem.154.5.1403","volume":"154","author":"JE Gootenberg","year":"1981","unstructured":"Gootenberg, J. E., Ruscetti, F. W., Mier, J. W., Gazdar, A. & Gallo, R. C. Human cutaneous T cell lymphoma and leukemia cell lines produce and respond to T cell growth factor. J. Exp. Med. 154, 1403\u20131418 (1981).","journal-title":"J. Exp. Med."},{"key":"4356_CR44","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1084\/jem.158.3.994","volume":"158","author":"H Mitsuya","year":"1983","unstructured":"Mitsuya, H. et al. Generation of an HLA-restricted cytotoxic T cell line reactive against cultured tumor cells from a patient infected with human T cell leukemia\/lymphoma virus. J. Exp. Med. 158, 994\u2013999 (1983).","journal-title":"J. Exp. Med."},{"key":"4356_CR45","first-page":"7682","volume":"50","author":"I Kubonishi","year":"1990","unstructured":"Kubonishi, I. et al. A Ki-1 (CD30)-positive T (E+, CD4+, Ia+)-cell line, DL-40, established from aggressive large cell lymphoma. Cancer Res. 50, 7682\u20137685 (1990).","journal-title":"Cancer Res."},{"key":"4356_CR46","first-page":"180","volume":"69","author":"N Emi","year":"1999","unstructured":"Emi, N. et al. CD4\u2212 and CD56-positive T-cell line, MTA, established from natural killer-like T-cell leukemia\/lymphoma. Int. J. Hematol. 69, 180\u2013185 (1999).","journal-title":"Int. J. Hematol."},{"key":"4356_CR47","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1038\/sj.leu.2401769","volume":"14","author":"M Yagita","year":"2000","unstructured":"Yagita, M. et al. A novel natural killer cell line (KHYG-1) from a patient with aggressive natural killer cell leukemia carrying a p53 point mutation. Leukemia 14, 922\u2013930 (2000).","journal-title":"Leukemia"},{"key":"4356_CR48","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1002\/cncr.25654","volume":"117","author":"MG Lechner","year":"2011","unstructured":"Lechner, M. G. et al. Breast implant-associated, ALK-negative, T-cell, anaplastic, large-cell lymphoma: establishment and characterization of a model cell line (TLBR-1) for this newly emerging clinical entity. Cancer 117, 1478\u20131489 (2011).","journal-title":"Cancer"},{"key":"4356_CR49","doi-asserted-by":"publisher","first-page":"4549","DOI":"10.1158\/1078-0432.CCR-12-0101","volume":"18","author":"MG Lechner","year":"2012","unstructured":"Lechner, M. G. et al. Survival signals and targets for therapy in breast implant-associated ALK\u2014anaplastic large cell lymphoma. Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res. 18, 4549\u20134559 (2012).","journal-title":"Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res."},{"key":"4356_CR50","first-page":"1214","volume":"8","author":"A del Mistro","year":"1994","unstructured":"del Mistro, A. et al. A CD30-positive T cell line established from an aggressive anaplastic large cell lymphoma, originally diagnosed as Hodgkin\u2019s disease. Leukemia 8, 1214\u20131219 (1994).","journal-title":"Leukemia"},{"key":"4356_CR51","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1056\/NEJM199204233261704","volume":"326","author":"TH Davis","year":"1992","unstructured":"Davis, T. H., Morton, C. C., Miller-Cassman, R., Balk, S. P. & Kadin, M. E. Hodgkin\u2019s disease, lymphomatoid papulosis, and cutaneous T-cell lymphoma derived from a common T-cell clone. N. Eng. J. Med. 326, 1115\u20131122 (1992).","journal-title":"N. Eng. J. Med."},{"key":"4356_CR52","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1182\/blood.V69.5.1307.1307","volume":"69","author":"ME Tweeddale","year":"1987","unstructured":"Tweeddale, M. E. et al. The presence of clonogenic cells in high-grade malignant lymphoma: a prognostic factor. Blood 69, 1307\u20131314 (1987).","journal-title":"Blood"},{"key":"4356_CR53","first-page":"406","volume":"24","author":"MJ Robertson","year":"1996","unstructured":"Robertson, M. J. et al. Characterization of a cell line, NKL, derived from an aggressive human natural killer cell leukemia. Exp. Hematol. 24, 406\u2013415 (1996).","journal-title":"Exp. Hematol."},{"key":"4356_CR54","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1002\/ijc.2910490218","volume":"49","author":"G Starkebaum","year":"1991","unstructured":"Starkebaum, G., Loughran, T. P. Jr, Waters, C. A. & Ruscetti, F. W. Establishment of an IL-2 independent, human T-cell line possessing only the p70 IL-2 receptor. Int. J. Cancer 49, 246\u2013253 (1991).","journal-title":"Int. J. Cancer"},{"key":"4356_CR55","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/BF00431220","volume":"279","author":"K Kaltoft","year":"1987","unstructured":"Kaltoft, K. et al. A continuous T-cell line from a patient with Sezary syndrome. Arch. Dermatol. Res. 279, 293\u2013298 (1987).","journal-title":"Arch. Dermatol. Res."},{"key":"4356_CR56","doi-asserted-by":"publisher","first-page":"7415","DOI":"10.1073\/pnas.77.12.7415","volume":"77","author":"BJ Poiesz","year":"1980","unstructured":"Poiesz, B. J. et al. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc. Natl. Acad. Sci. USA 77, 7415\u20137419 (1980).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"4356_CR57","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1038\/294770a0","volume":"294","author":"I Miyoshi","year":"1981","unstructured":"Miyoshi, I. et al. Type C virus particles in a cord T-cell line derived by co-cultivating normal human cord leukocytes and human leukaemic T cells. Nature 294, 770\u2013771 (1981).","journal-title":"Nature"},{"key":"4356_CR58","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1126\/science.6600519","volume":"219","author":"M Popovic","year":"1983","unstructured":"Popovic, M. et al. Isolation and transmission of human retrovirus (human t-cell leukemia virus). Science 219, 856\u2013859 (1983).","journal-title":"Science"},{"key":"4356_CR59","doi-asserted-by":"publisher","first-page":"443","DOI":"10.3109\/10428199609093442","volume":"21","author":"Y Yamada","year":"1996","unstructured":"Yamada, Y. et al. Features of the cytokines secreted by adult T cell leukemia (ATL) cells. Leuk. Lymphoma 21, 443\u2013447 (1996).","journal-title":"Leuk. Lymphoma"},{"key":"4356_CR60","doi-asserted-by":"crossref","first-page":"6892","DOI":"10.1128\/jvi.65.12.6892-6899.1991","volume":"65","author":"N Arima","year":"1991","unstructured":"Arima, N. et al. Human T-cell leukemia virus type I Tax induces expression of the Rel-related family of kappa B enhancer-binding proteins: evidence for a pretranslational component of regulation. J. Virol. 65, 6892\u20136899 (1991).","journal-title":"J. Virol."},{"key":"4356_CR61","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/0165-4608(92)90215-T","volume":"59","author":"S Miyanishi","year":"1992","unstructured":"Miyanishi, S. & Ohno, H. Characterization of a novel T-cell lymphoma cell line established from a patient with systemic lupus erythematosus-associated lymphoma. Cancer Genet. Cytogenet. 59, 199\u2013205 (1992).","journal-title":"Cancer Genet. Cytogenet."},{"key":"4356_CR62","first-page":"740","volume":"166","author":"F Iorio","year":"2016","unstructured":"Iorio, F. et al. A landscape of pharmacogenomic interactions in. Cancer Cell. 166, 740\u2013754 (2016).","journal-title":"Cancer Cell."},{"key":"4356_CR63","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/nature19057","volume":"536","author":"M Lek","year":"2016","unstructured":"Lek, M. et al. Analysis of protein-coding genetic variation in 60,706 humans. Nature 536, 285\u2013291 (2016).","journal-title":"Nature"},{"key":"4356_CR64","doi-asserted-by":"publisher","first-page":"2520","DOI":"10.1093\/bioinformatics\/bts480","volume":"28","author":"J Koster","year":"2012","unstructured":"Koster, J. & Rahmann, S. Snakemake\u2014a scalable bioinformatics workflow engine. Bioinformatics 28, 2520\u20132522 (2012).","journal-title":"Bioinformatics"},{"key":"4356_CR65","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1038\/nbt.1621","volume":"28","author":"C Trapnell","year":"2010","unstructured":"Trapnell, C. et al. Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. Nat. Biotechnol. 28, 511\u2013515 (2010).","journal-title":"Nat. Biotechnol."},{"key":"4356_CR66","doi-asserted-by":"crossref","unstructured":"Haas, B. et al. STAR-Fusion: Fast and accurate fusion transcript detection from RNA-Seq. Preprint at\u00a0https:\/\/doi.org\/10.1101\/120295 (2017).\u00a0","DOI":"10.1101\/120295"},{"key":"4356_CR67","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2011-12-3-r22","volume":"12","author":"A Roberts","year":"2011","unstructured":"Roberts, A., Trapnell, C., Donaghey, J., Rinn, J. L. & Pachter, L. Improving RNA-Seq expression estimates by correcting for fragment bias. Genome Biol. 12, R22 (2011).","journal-title":"Genome Biol."},{"key":"4356_CR68","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1371\/journal.pgen.0030161","volume":"3","author":"JT Leek","year":"2007","unstructured":"Leek, J. T. & Storey, J. D. Capturing heterogeneity in gene expression studies by surrogate variable analysis. PLoS Genet. 3, 1724\u20131735 (2007).","journal-title":"PLoS Genet."},{"key":"4356_CR69","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1093\/bioinformatics\/btp324","volume":"25","author":"H Li","year":"2009","unstructured":"Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows\u2013Wheeler transform. Bioinformatics 25, 1754\u20131760 (2009).","journal-title":"Bioinformatics"},{"key":"4356_CR70","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1038\/ng.3984","volume":"49","author":"RM Meyers","year":"2017","unstructured":"Meyers, R. M. et al. Computational correction of copy number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells. Nat. Genet. 49, 1779\u20131784 (2017).","journal-title":"Nat. Genet."},{"key":"4356_CR71","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1158\/2159-8290.CD-16-0154","volume":"6","author":"AJ Aguirre","year":"2016","unstructured":"Aguirre, A. J. et al. Genomic copy number dictates a gene-independent cell response to CRISPR\/Cas9 targeting. Cancer Discov. 6, 914\u2013929 (2016).","journal-title":"Cancer Discov."},{"key":"4356_CR72","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/nbt.3437","volume":"34","author":"JG Doench","year":"2016","unstructured":"Doench, J. G. et al. Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9. Nat. Biotechnol. 34, 184\u2013191 (2016).","journal-title":"Nat. Biotechnol."},{"key":"4356_CR73","doi-asserted-by":"crossref","unstructured":"Edgar. R., Domrachev, M. & Lash, A. E. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res. 30, 207-210 (2002).\u00a0","DOI":"10.1093\/nar\/30.1.207"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-018-04356-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-018-04356-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-018-04356-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T14:02:54Z","timestamp":1671544974000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-018-04356-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,22]]},"references-count":73,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["4356"],"URL":"https:\/\/doi.org\/10.1038\/s41467-018-04356-9","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,22]]},"assertion":[{"value":"21 February 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.M.W. received research support from Novartis and Aileron and is a paid consultant for Novartis. S.S., J-G.R., V.G., D.A.A., and M.A. are employees of Aileron. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2024"}}